ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1837

Genetic Susceptibility Loci for Systemic Lupus Erythematosus in the Dominican Republic Population

Esthela Loyo1, Zheng Liu2, Carmen Tineo3, Paola Gottschalk3, Glenny Paulino3, Yangsheng Yu2, Yinshi Yue2, Michelene Hearth-Holmes4, Zhixin Zhang5 and Kaihong Su2, 1Departamento de Reumatologia, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, 2Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, Hospital Regional Universitario José Ma Cabral Baez, Santiego, Dominican Republic, 4Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, 5Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus and genetics

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with marked disparities in prevalence and disease characteristics among different populations. Those disparities are believed to result from both genetic and environmental factors. The purpose of this study is to identify genetic susceptibility alleles for SLE in the Dominican Republic (DR) population which has a high prevalence for SLE.

Methods: SLE patients (n = 208) who fulfilled the 1997 revised American College of Rheumatology criteria for the classification of SLE and age/sex-matched healthy controls (n = 205) from the DR were recruited for this case-control study. Genomic DNA was prepared from whole blood and subjected to Sequenom MassARRAY iPLEX genotyping analyses for 42 selected single nucleotide polymorphisms (SNPs). The allele frequencies in SLE patients and healthy controls were compared using Pearson Chi-Square or Fisher’s Exact test.

Results: Among the 19 human leukocyte antigen (HLA) gene alleles analyzed, HLA-DQA1 (rs 9271366) shows the strongest association with SLE (OR = 5.48, p = 0.0001, Pearson Chi-Square test). SNPs at HLA-DRA (rs6903608, rs9268880, and rs9268979) and HLA-DRB2 (rs9271055) also contribute to SLE susceptibility in the DR population (p = 0.0086, OR = 2.09; p = 0.0061, OR = 2.21; p = 0.0012, OR = 2.86; and p = 0.0059, OR = 3.27, respectively). Among the 23 non-HLA gene alleles analyzed, SNP1858C/T (rs2476601) in the tyrosine phosphatase, non-receptor type 22 (PTPN22) gene shows the highest odds ratio for SLE (OR = 6.54, p = 0.038, Pearson Chi-Square test). SNPs in the STAT4 gene (rs11889341), PMS2 gene (rs1860460), and TNFSF4 gene (rs2205960) also contribute to SLE susceptibility in the DR population (p = 0.025, OR = 2.2; p = 0.032, OR = 1.7; and p = 0.035, OR = 2.39, respectively). However, SNPs in the IRF5 (rs12537284 and rs2070197), BLK (rs13277113), and TNFAIP3 (rs 5029939) genes that have been frequently identified as SLE susceptibility alleles in other populations do not show association with SLE in the DR population (p = 0.824, 0.4, 0.468, and 0.896, respectively).

Conclusion: SNPs in the HLA-DQA1, HLA-DRA, and HLA-DRB2 alleles and non-HLA genes PTPN22, STAT4, PMS2, and TNFSF4 contribute to SLE susceptibility in the DR population. However, SNPs in the IRF5, BLK, and TNFAIP3 genes may not contribute to SLE susceptibility in the DR population. This is the first study focusing on SLE patients from the DR who may have unique genetic risk factors for the development of SLE.


Disclosure: E. Loyo, None; Z. Liu, None; C. Tineo, None; P. Gottschalk, None; G. Paulino, None; Y. Yu, None; Y. Yue, None; M. Hearth-Holmes, None; Z. Zhang, None; K. Su, None.

To cite this abstract in AMA style:

Loyo E, Liu Z, Tineo C, Gottschalk P, Paulino G, Yu Y, Yue Y, Hearth-Holmes M, Zhang Z, Su K. Genetic Susceptibility Loci for Systemic Lupus Erythematosus in the Dominican Republic Population [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/genetic-susceptibility-loci-for-systemic-lupus-erythematosus-in-the-dominican-republic-population/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-susceptibility-loci-for-systemic-lupus-erythematosus-in-the-dominican-republic-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology